Log in

NASDAQ:EYENEyenovia Stock Price, Forecast & News

$2.85
+0.04 (+1.42 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.82
Now: $2.85
$2.89
50-Day Range
$2.72
MA: $3.03
$3.37
52-Week Range
$1.11
Now: $2.85
$5.06
Volume82,664 shs
Average Volume100,237 shs
Market Capitalization$56.37 million
P/E RatioN/A
Dividend YieldN/A
Beta2.33
Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
Read More
Eyenovia logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.13 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYEN
CUSIPN/A
Phone917-289-1117

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.71 per share

Profitability

Net Income$-21,160,000.00

Miscellaneous

EmployeesN/A
Market Cap$56.37 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive EYEN News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.

Eyenovia (NASDAQ:EYEN) Frequently Asked Questions

How has Eyenovia's stock been impacted by COVID-19 (Coronavirus)?

Eyenovia's stock was trading at $2.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EYEN stock has decreased by 1.7% and is now trading at $2.85. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Eyenovia?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eyenovia.

When is Eyenovia's next earnings date?

Eyenovia is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Eyenovia.

How were Eyenovia's earnings last quarter?

Eyenovia Inc (NASDAQ:EYEN) issued its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.01. View Eyenovia's earnings history.

What price target have analysts set for EYEN?

3 brokerages have issued 1-year price targets for Eyenovia's shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate Eyenovia's stock price to reach $6.00 in the next year. This suggests a possible upside of 110.5% from the stock's current price. View analysts' price targets for Eyenovia.

Has Eyenovia been receiving favorable news coverage?

News headlines about EYEN stock have trended somewhat positive recently, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eyenovia earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news about Eyenovia.

Are investors shorting Eyenovia?

Eyenovia saw a drop in short interest during the month of June. As of June 15th, there was short interest totaling 166,400 shares, a drop of 33.5% from the May 31st total of 250,200 shares. Based on an average daily volume of 55,000 shares, the short-interest ratio is currently 3.0 days. Currently, 1.5% of the shares of the company are short sold. View Eyenovia's Current Options Chain.

Who are some of Eyenovia's key competitors?

What other stocks do shareholders of Eyenovia own?

Who are Eyenovia's key executives?

Eyenovia's management team includes the following people:
  • Dr. Tsontcho Ianchulev M.P.H., M.D., MPH, CEO, Chief Medical Officer & Director (Age 46)
  • Ms. Jennifer Clasby, VP of Clinical Operations (Age 65)
  • Mr. Luke Clauson, VP of R&D (Age 40)
  • Mr. John P. Gandolfo, CFO & Sec. (Age 58)
  • Mr. Michael M. Rowe, VP of Marketing

When did Eyenovia IPO?

(EYEN) raised $30 million in an initial public offering (IPO) on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ acted as the underwriters for the IPO.

What is Eyenovia's stock symbol?

Eyenovia trades on the NASDAQ under the ticker symbol "EYEN."

How do I buy shares of Eyenovia?

Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eyenovia's stock price today?

One share of EYEN stock can currently be purchased for approximately $2.85.

How big of a company is Eyenovia?

Eyenovia has a market capitalization of $56.37 million. The company earns $-21,160,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.

What is Eyenovia's official website?

The official website for Eyenovia is www.eyenoviabio.com.

How can I contact Eyenovia?

Eyenovia's mailing address is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.